BioSpace News Archive

Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2022 on Thursday, November 3, 2022, before the market opens.

Morphic Therapeutic announced the completion of targeted enrollment of 30 patients ahead of schedule for the main cohort of the EMERALD-1 phase 2a study of MORF-057 in patients with moderate to severe ulcerative colitis.

Ocelot Bio to Present Data Highlighting Pharmacodynamic Activity and Safety of OCE-205 at AASLD The Liver Meeting.

Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors.

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the preclinical development of RT-111, a RaniPill GO capsule containing an ustekinumab biosimilar, as part of a corporate and pipeline update.

Enosi Therapeutics has announced that Enosi CEO and CSO, Dr. H. Michael Shepard, will be presenting the company’s preclinical work in a presentation titled “High affinity ligand traps derived from he EGFR and HER3 are efficacious in murine models of cancer and autoimmune disease” at the ENA 2022 Symposium being held in Barcelona October 26-28, 2022.

Urethral stricture, blocking the passage of urine from the bladder in men, could be solved by BEES-HAUS cell therapy, a novel autologous buccal mucosal cell-based approach as reported by Dr. Akio Horiguchi an eminent urologist.

An international collaboration between Bruce Power, Isogen and ITM Isotope Technologies Munich SE, announced the commencement of commercial production of lutetium-177.

Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced the appointment of Jens Würthner, MD, PhD, as Chief Medical Officer.

Trevena, Inc. today announced that an abstract entitled, “A Randomized Double-blind Trial Comparing Oliceridine And Morphine On Ventilation In An Elderly Population” (BOC10) has been accepted for podium presentation in the “Best of Abstracts: Clinical Science” session at the ANESTHESIOLOGY®2022 Annual Meeting, being held October 21-25, 2022 in New Orleans, LA.